NASDAQ:LUMO

Lumos Pharma (LUMO) Stock Forecast, Price & News

$3.88

+0.29 (+8.08%)

(As of 06/2/2023 ET)

Compare

Today's Range: $3.60
▼
$3.92
50-Day Range: $3.01
▼
$3.96
52-Week Range: $2.95
▼
$9.56

Volume: 20,008 shs
Average Volume: 16,755 shs
Market Capitalization: $31.70 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.67

Lumos Pharma MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 355.3% Upside
$17.67 Price Target
Short Interest: Bearish
3.73% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.28
Based on 2 Articles This Week
Insider Trading: Selling Shares
$7,240 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.88) to ($2.96) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

406th out of 983 stocks

Pharmaceutical Preparations Industry

193rd out of 486 stocks

3.4

Analyst's Opinion

Consensus Rating
Lumos Pharma has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.67, Lumos Pharma has a forecasted upside of 355.3% from its current price of $3.88.
Amount of Analyst Coverage
Lumos Pharma has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
3.73% of the float of Lumos Pharma has been sold short.
Short Interest Ratio / Days to Cover
Lumos Pharma has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.
Change versus previous month
Short interest in Lumos Pharma has recently increased by 1.26%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Lumos Pharma does not currently pay a dividend.
Dividend Growth
Lumos Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LUMO.

2.4

News and Social Media Coverage

News Sentiment
Lumos Pharma has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Lumos Pharma this week, compared to 1 article on an average week.
MarketBeat Follows
1 people have added Lumos Pharma to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lumos Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,240.00 in company stock.
Percentage Held by Insiders
23.70% of the stock of Lumos Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 30.53% of the stock of Lumos Pharma is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Lumos Pharma are expected to grow in the coming year, from ($3.88) to ($2.96) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lumos Pharma is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lumos Pharma is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Lumos Pharma has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Lumos Pharma (NASDAQ:LUMO) Stock

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.

Receive LUMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lumos Pharma and its competitors with MarketBeat's FREE daily newsletter.

LUMO Stock News Headlines

May 31, 2023 | finance.yahoo.com

Lumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare Conference

May 28, 2023 | finance.yahoo.com

Daniel Farb Buys 22% More Lumos Pharma Shares

June 2, 2023 | Vantage Point (Ad)

We Called (ARWR) In Advance, Which Stocks Are Next?

Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.

May 26, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Hold Rating on Spectrum Pharmaceuticals (SPPI)

May 25, 2023 | finance.yahoo.com

Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st

May 22, 2023 | finance.yahoo.com

Lumos Pharma to Participate in World Orphan Drug Congress USA

May 16, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Inhibikase Therapeutics (IKT)

May 15, 2023 | americanbankingnews.com

Financial Comparison: Lumos Pharma (NASDAQ:LUMO) and IDEAYA Biosciences (NASDAQ:IDYA)

June 2, 2023 | Behind the Markets (Ad)

"How war impacts the stock market"

Russia's invasion of Ukraine has already sent the stock market down 10%. But that's just the opening act for the new Russia-China Alliance. There's a major event involving China that's heating up... and it could boil over as soon as April 16th, 2023. Click Here to Learn How to Protect Your Retirement

May 11, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on TRACON Pharmaceuticals (TCON)

May 10, 2023 | americanbankingnews.com

Q2 2023 EPS Estimates for Lumos Pharma, Inc. (NASDAQ:LUMO) Raised by Analyst

May 8, 2023 | finance.yahoo.com

Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES)

May 5, 2023 | msn.com

HC Wainwright & Co. Reiterates Lumos Pharma (LUMO) Buy Recommendation

May 4, 2023 | finanznachrichten.de

Lumos Pharma, Inc.: Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates

May 4, 2023 | marketwatch.com

8-K: LUMOS PHARMA, INC.

May 3, 2023 | msn.com

Lumos Pharma GAAP EPS of -$0.89 beats by $0.24, revenue of $0.69M beats by $0.57M

May 3, 2023 | msn.com

Lumos Pharma: Q1 Earnings Insights

May 3, 2023 | finance.yahoo.com

Lumos Pharma (LUMO) Reports Q1 Loss, Tops Revenue Estimates

May 3, 2023 | finance.yahoo.com

Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates

May 1, 2023 | americanbankingnews.com

Lumos Pharma (LUMO) to Release Quarterly Earnings on Wednesday

April 27, 2023 | finance.yahoo.com

Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)

April 19, 2023 | finance.yahoo.com

Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023

March 24, 2023 | markets.businessinsider.com

Oppenheimer Remains a Buy on Soleno Therapeutics (SLNO)

March 22, 2023 | finance.yahoo.com

We Think Lumos Pharma (NASDAQ:LUMO) Needs To Drive Business Growth Carefully

March 9, 2023 | finance.yahoo.com

Lumos Pharma to Participate in Oppenheimer’s 33rd Annual Healthcare Conference Held Virtually March 13-15, 2023

March 6, 2023 | insidermonkey.com

Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2022 Earnings Call Transcript

March 5, 2023 | finance.yahoo.com

Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology

See More Headlines

LUMO Price History

30 days | 90 days | 365 days | Advanced Chart

LUMO Company Calendar

Last Earnings: 5/03/2023
Today: 6/02/2023
Next Earnings (Estimated): 8/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LUMO
CUSIP: N/A
CIK: 1126234
Web: www.lumos-pharma.com
Phone: (512) 215-2630
Fax: 515-296-3520
Employees: 29
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $17.67
High Stock Price Forecast: $28.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +363.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.67)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-31,060,000.00
Net Margins: -1,459.25%
Pretax Margin: -1,459.87%
Return on Equity: -48.26%
Return on Assets: -40.83%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.61
Quick Ratio: 12.61

Sales & Book Value

Annual Sales: $1.52 million
Price / Sales: 20.48
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.43 per share
Price / Book: 0.59

Miscellaneous

Outstanding Shares: 8,170,000
Free Float: 6,234,000
Market Cap: $31.13 million
Optionable: Not Optionable
Beta: 0.95

Key Executives

Richard J. Hawkins
Chairman & Chief Executive Officer

John C. McKew
President & Chief Scientific Officer

Robert J. Davis
Vice President-Clinical Operations

Lori Lawley
Chief Financial Officer

David B. Karpf
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LUMO Stock - Frequently Asked Questions

Should I buy or sell Lumos Pharma stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lumos Pharma in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LUMO shares.
View LUMO analyst ratings or view top-rated stocks.
What is Lumos Pharma's stock price forecast for 2023?: 5 brokerages have issued 1 year price objectives for Lumos Pharma's stock. Their LUMO share price forecasts range from $7.00 to $28.00. On average, they expect the company's share price to reach $17.67 in the next twelve months. This suggests a possible upside of 363.7% from the stock's current price.
View analysts price targets for LUMO or view top-rated stocks among Wall Street analysts.
How have LUMO shares performed in 2023?: Lumos Pharma's stock was trading at $3.61 at the start of the year. Since then, LUMO stock has increased by 5.5% and is now trading at $3.81.
View the best growth stocks for 2023 here.
When is Lumos Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our LUMO earnings forecast.
How were Lumos Pharma's earnings last quarter?: Lumos Pharma, Inc. (NASDAQ:LUMO) posted its earnings results on Wednesday, May, 3rd. The company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.23. The firm had revenue of $0.69 million for the quarter, compared to analysts' expectations of $0.31 million. Lumos Pharma had a negative trailing twelve-month return on equity of 48.26% and a negative net margin of 1,459.25%.
What other stocks do shareholders of Lumos Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Lumos Pharma investors own include Advanced Micro Devices (AMD), Agilent Technologies (A), Air Lease (AL), Ampio Pharmaceuticals (AMPE), Bionano Genomics (BNGO), Chimerix (CMRX), Compagnie de Saint-Gobain (CODYY) and

What is Lumos Pharma's stock symbol?: Lumos Pharma trades on the NASDAQ under the ticker symbol "LUMO."
Who are Lumos Pharma's major shareholders?: Lumos Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.81%), Marquette Asset Management LLC (0.38%), Greenwich Wealth Management LLC (0.37%) and Private Advisor Group LLC (0.24%). Insiders that own company stock include James E Flynn, John C Mckew, Kevin M Lalande, Kevin M Lalande, Richard J Hawkins and Thomas A Raffin.
View institutional ownership trends.
How do I buy shares of Lumos Pharma?: Shares of LUMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Lumos Pharma's stock price today?: One share of LUMO stock can currently be purchased for approximately $3.81.
How much money does Lumos Pharma make?: Lumos Pharma (NASDAQ:LUMO) has a market capitalization of $31.13 million and generates $1.52 million in revenue each year. The company earns $-31,060,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis.
How can I contact Lumos Pharma?: Lumos Pharma's mailing address is 4200 MARATHON BLVD. SUITE 200, AUSTIN TX, 78756. The official website for the company is www.lumos-pharma.com. The company can be reached via phone at (512) 215-2630, via email at investor@linkp.com, or via fax at 515-296-3520.

This page (NASDAQ:LUMO) was last updated on 6/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial